Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates

Journal of Medicinal Chemistry

Volumn 50, Issue 14, 2007, Pages 3340-3353

  Xiong, Yu ^a   Zhao, Ming ^b   Wang, Chao ^a   Heng, Wei Chang ^c   Peng, Shiqi ^b  

^a PEKING UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c C S Bio Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ARGINYLGLYCYLASPARTIC ACID; CALCIUM ION; ESTRADIOL 17 ARGINYLGLYCYLASPARTIC ACID; ESTRADIOL 3 ARGINYLGLYCYLASPARTIC ACID; ESTROGEN ARGINYLGLYCYLASPARTIC ACID; ESTROGEN DERIVATIVE; ESTRONE 3 ARGINYLGLYCYLASPARTIC ACID; MINERAL; PHOSPHORUS; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MINERAL; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DRUG STRUCTURE; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; MOUSE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS;

ALKALINE PHOSPHATASE; ANIMALS; CALCIUM; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HYPERPLASIA; MICE; OLIGOPEPTIDES; ORGAN SIZE; OSTEOPOROSIS; OVARIECTOMY;

EID: 34447514124     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070242a     Document Type: Article

References (22)

1. Davidson, M.; DeSimone, M. E. Confronting osteoporosis: What we know, where we're headed. Clin. Rev. 2002, 12, 76-82.
2. Amin, Shreyasee.; Zhang, Yuqinq.; Felson, David T.; Sawin, Clark T.; Hannan, Marian T.; Wilson, Peter W. F. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham study. Am. J. Med. 2006, 119, 426-433.
3. Spencer, C. P.; Morris, E. P.; Rymer, J. M. Selective estrogen receptor modulators: Women's penacea for the next millennium? Am. J. Obstet. Gynecol. 1999, 180, 763-770.
4. Michael, J. S. Selective estrogen receptor modulators: The ideal estrogen replacement. 2001, 8, 25-30.
5. Hosking, D.; Chilvers, C. E.; Christiansen, C.; Ravn, P.; Wasnich, R.; Ross, P.; McClung, M.; Balske, A.; Thompson, D.; Daley, M.; Yates, A. J. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early postmenopausal intervention cohort study group. N. Engl. J. Med. 1998, 338, 485-492.
6. Stampter, M.; Colditz, G. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidimiological evidence. Prev. Med. 1991, 20, 47-63.
7. Michealsson, K.; Baron, J. A.; Farahmand, B. Y.; Johnell, O.; Magnusson, C.; Persson, P. G.; Persson, I.; Ljunghall, S. Hormone replacement therapy and risk of hip fracture: Population based case-control study. The Swedish hip fracture study group. Br. Med. J. 1998, 316, 1858-1863.
8. Colditz, G. A.; Hankinson, S. E.; Hunter, D. J.; Willett, W. C.; Manson, J. E.; Stampfer, M. J. The use of estrogen and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 1995, 332, 1589-1593.
9. Mishell, D. J. Estrogen replacement therapy: An overview. Am. J. Obstet. Gynecol. 1989, 161 (6 Pt 2), 1825-1827.
10. Witt, D. M.; Lousberg, T. R. Controversies surrounding estrogen use in postmenopausal women. Ann. Pharmaeother. 1997, 31, 745-755.
11. Josse, R. G. Effect of ovarian hormonal therapy on skeletal and estraskeletal tissues in women. Can. Med. Assoc. J. 1996, 155, 929-934.
12. Wang, C.; Zhao, M.; Yang, J.; Peng, S. Q. Synthesis and analgesic effects of kyotorphin-steroid linkers. Steroids 2001, 66, 811-815.
13. Wang, C.; Zhao, M.; Peng, S. Q. The synthesis and immunosuppressive activities of steroid-urotoxin linkers. Bioorg. Med. Chem. 2004, 12, 4403-4421.
14. Wang, C.; Cui, W. N.; Zhao, M.; Yang, J.; Peng, S. Q. Studies on the synthesis and anti-osteoporosis of estrogen-GHRPS linkers. Bioorg. Med. Chem. Lett. 2003, 13, 143-146.
15. Oursler, M. J. Estrogen regulation of gene expression in osteoblasts and osteoclasts. Crit. Rev. Eukaryotic Gene Expression 1998, 8, 125-140.
16. Majeska, K. J.; Ryaby, J. T.; Einhorn, T. A. Direct Modulation of osteoblastic activity with estrogen. J. Bone J. Surg., Am. Vol. 1994, 76, 713-721.
17. Zang, X. Y.; Tan, Y. B.; Pang, Z. L.; Zhang, W. Z.; Zhao, J. Effects of parathyroid hormone and estradiol on proliferation and function of human osteoblasts from fetal long bone: An in vitro study. Chin. Med. J. 1994, 107, 600-603.
18. Horton, M. A.; Taylor, M. L.; Arnett, T. R.; Helfrich, M. H. Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antidy 23C6 inhibit dentine resorption and cell spreading by osteoclast. Exp. Cell Res. 1991, 195, 368-375.
19. Thompson, D. D.; Simmons, H. A.; Pirie, C. M.; Ke, H. Z. FDA guidelines and animal models for osteoporosis. Bone 1995, 17, 125s-133s.
20. Suzuki, Y.; Okonogi, H.; Shimizu, H. Effect of erythroblust calcium ion concentration on the micronucleus test: Mutation research/environmental mutagenesis and related subjects. 1996, 357, 236s.
21. Titov, V. N.; Tvorogova, M. G. Blood serum inorganic phosphorus: diagnostic significance and method of determination (review of the literature). Lab. Delo. 1991, 12, 10-16.
22. Wright, D. S.; Friedman, M. L.; Jenkins, S. H.; Heineman, W. R.; Halsall, H. B. Sequestration electrochemistry: The interaction of chlorpromazine and human orosomucoid. Anal. Biochem. 1988, 168, 290-293.